Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Alumis Inc. Common Stock

A company that transforms the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies.

Alumis

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. 

Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. 

Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.

Today we announced the pricing of our initial public offering: https://bit.ly/3zwhdvh #NasdaqListed

Today, we honor #Juneteenth, celebrating freedom, resilience, and progress. As we reflect on this important day in history, we’re committed to fostering diversity and inclusion at Alumis. #FreedomDay

Alumis’ clinical development team attended the EULAR - European Alliance of Associations for Rheumatology 2024 Congress earlier this month in Vienna! With the goal of driving progress in the clinical care of people with rheumatic diseases, the annual meeting brings together patients, health professionals, rheumatologists and industry partners to showcase the latest scientific breakthroughs in clinical, translational, and basic research. We were thrilled to be part of this meeting as we advance our #lupus clinical trial LUMUS! #EULAR2024

This #PrideMonth, we celebrate the vibrant LGBTQIA+ community and recognize their invaluable contributions to science and biotechnology. Together, we stand proud in our commitment to diversity, inclusion, and equality. #Pride2024

Did you know that women are disproportionately affected by #lupus? To learn more about lupus this #LupusAwarenessMonth, check out resources and information from @LupusResearch: https://lnkd.in/esmUVvvw

We are thrilled to announce our initial public offering, trading on Nasdaq under the ticker $ALMS! This achievement wouldn't have been possible without the relentless dedication of our incredible team, as well as the support of our Board of Directors and investors. Thank you to everyone who helped us reach this critical milestone in support of our mission to improve the lives of patients with immune-mediated diseases. #NasdaqListed

	Mar '23	Mar '24	Jun '24
account payables		6.84M -
accumulated other comprehensive income loss	-195.24M -	-1K 100.00%	-1K 0%
cash and cash equivalents	-92.86M -	112.18M 220.80%	155.22M 38.36%
cash and short term investments	92.86M -	133.84M 44.12%	209.64M 56.64%
common stock		1K -	1K 0%
deferred revenue		-6.84M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt		30.46M -
long term investments		1.02M -	1.02M 0%
net debt	92.86M -	-80.11M 186.26%	-123.65M 54.35%
net receivables		614K -	897K 46.09%
other assets		1 -
other current assets		6.79M -	14.31M 110.76%
other current liabilities		15.53M -	31.89M 105.36%
other liabilities			1 -
other non current assets	-92.86M -	242.00K 100.26%	4.35M 1,699.18%
other non current liabilities		13.28M -	31.28M 135.57%
othertotal stockholders equity		28.24M -	31.92M 13.03%
preferred stock	285.47M -	495.57M 73.60%	639.24M 28.99%
property plant equipment net		34.86M -	34.95M 0.24%
retained earnings		-414.17M -	-470.68M 13.64%
short term debt		1.62M -	1.52M 5.87%
short term investments	185.73M -	21.66M 88.34%	54.42M 151.31%
tax assets
tax payables
total assets		177.38M -	265.18M 49.50%
total current assets	92.86M -	141.25M 52.10%	224.86M 59.19%
total current liabilities		23.99M -	33.41M 39.29%
total debt		32.08M -	31.57M 1.57%
total investments	185.73M -	22.68M 87.79%	55.45M 144.48%
total liabilities		67.73M -	64.70M 4.47%
total liabilities and stockholders equity	90.23M -	177.38M 96.58%	265.18M 49.50%
total non current assets	-92.86M -	36.13M 138.90%	40.32M 11.61%
total non current liabilities		43.74M -	31.28M 28.47%
total stockholders equity	90.23M -	109.65M 21.52%	200.48M 82.84%

ALMS

COM:ALUMIS

Alumis

Last Close

9.64

21/11 21:00

Market Cap

668.34M

Beta: -

Volume Today

80.08K

Avg: -

Preview